All News

Deferasirox is indicated for treating chronic iron overload caused by repeated blood transfusions in patients age 2 years and older.

The Prescription Drug User Fee Act date, the FDA action data for this supplemental application, is scheduled for the second quarter of 2020.

A study suggests that even brief art-making interventions can be beneficial for stressed caregivers of patients with cancer.

Annoying work habits can set the tone for lower productivity and teamwork in the pharmacy.

Top news of the day from across the health care landscape.

Researchers investigate whether on-demand pre-exposure prophylaxis was similarly effective among individuals with lower exposure to HIV risk.

The treatment is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation, according to Novo Nordisk.

According to the study authors, such “anti-austerity agents” represent a promising approach to cancer chemotherapy.

Could tadalafil be causing a patient to feel dizzy?

Top news of the week from Specialty Pharmacy Times

The study led to insight on the process of tuberculosis bacillus infection as well as a potential drug treatment.

At the recent ASHP (American Society of Health-System Pharmacists) Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada, 3 speakers discussed new developments in influenza management.

The bill would have given the state's superintendent of insurance licensing and regulatory authority over pharmacy benefit managers (PBMs).1

Top news of the day from across the health care landscape.

Novadoz Pharmaceuticals, who markets the product, has commenced shipping of the drug, available in bottles of 30 tablets.

You wrote to us, and we listened! Here are the top social comments for the 2019 year.

Study findings presented at the American Society of Nephrology’s Kidney Week 2019 suggest a link between chronic use of proton pump inhibitors and progression of kidney function decline in chronic kidney disease.

From newsworthy moments to groundbreaking research, these are the most popular articles published on Pharmacy Times® during 2019.

Officials with the FDA have approved olaparib (Lynparza, AstraZeneca and Merck) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

Stuck in the pharmacy during the New Year’s Eve festivities? This Pharmacy Times countdown has everything you need for celebrating the holiday with your pharmacy team.

Deeb Eid, PharmD, is creator of the Pharmacy Universe podcast on Spreaker. An associate professor and experiential coordinator at Ferris State University College of Pharmacy in Grand Rapids, MI, Eid speaks with pharmacy industry guests to educate and engage listeners about the profession.

Individuals with HIV have more QT interval variability than those without the disease, which may lead to the increased risk of sudden cardiac death.

Researchers may have found a way to stop the driving force at a molecular level behind acute lymphoblastic leukemia.

Ashley M. Rogers, PharmD, BCPS, has been named the 2019 Distinguished Young Pharmacist of the Year in Massachusetts.

Officials with the FDA have approved Eisai’s lemborexant (Dayvigo) 5 mg and 10 mg for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Officials with the FDA have approved Intra-Cellular Therapies’ lumateperone (Caplyta) for the treatment of schizophrenia in adults, according to the company.

What classic Christmas movie character fits best with your pharmacy profession?

Patients with epilepsy treated with perampanel during routine clinical care had favorable retention rates and sustained efficacy.